• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Idorsia submits investigational insomnia treatment daridorexant to the EMA pharmatimes
    March 03, 2021
    Swiss biotech company Idorsia has submitted a marketing authorisation application to the European Medicines Agency (EMA) for its investigational insomnia treatment daridorexant.
  • Idorsia Partners with Syneos Health contractpharma
    September 01, 2020
    ​Idorsia Ltd and Syneos Health have formed a commercial relationship for the U.S. commercialization of Idorsia’s daridorexant, a new dual orexin receptor antagonist being investigated for the treatment of insomnia.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service